Blog

Lauren Brown: Another insightful article out of the AURORA collaboration

Photo taken from www.clinical-lung-cancer.com

May 10, 2024, 14:58

Lauren Brown: Another insightful article out of the AURORA collaboration

Lauren Brown, PhD Candidate at Westmead Institute for Medical Research, University of Sydney & Medical Oncology Fellow at Westmead and Blacktown Hospitals, made the following post on X:

“Another insightful article out of the AURORA collaboration. Patients with KRAS, or PDL1 ≥50% are more likely to complete 24-months of pembro for NSCLC. Patients with oligoprogression in the brain treated with RT can still have enduring responses.”

Read the article.
Source: Lauren Brown/X

AURORA collaboration Blacktown Hospital brain metastases cancer cancer treatment KRAS mutation Lauren Brown Medical Oncology Fellow Medical Research NSCLC oligoprogression OncoDaily Oncology PD-L1 pembrolizumab PhD Candidate radiotherapy Research University of Sydney Westmead Hospital Westmead Institute for Medical Research

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage